Correlates of immune protection in HIV-1 infection: What we know, what we don't know, what we should know

Nature Medicine

Volumn 10, Issue 8, 2004, Pages 806-810

  Pantaleo, Giuseppe ^a   Koup, Richard A ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2;

ANTIBODY PRODUCTION; CLINICAL TRIAL; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOLOGICAL MONITORING; MEMORY CELL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; VACCINATION;

AIDS VACCINES; ANTIBODY FORMATION; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; MONITORING, IMMUNOLOGIC; VIRUS DISEASES;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 4043060710     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0804-806     Document Type: Review

References (50)

1. Seet, B.T. et al. Poxviruses and immune evasion. Annu. Rev. Immunol. 21, 377-423 (2003).
2. Griffin, D.E. Immune responses during measles virus infection. Curr. Top. Microbiol. Immunol. 191, 117-134 (1995).
3. Arvin, A.M. Immune responses to varicella-zoster virus. Infect. Dis. Clin. North Am. 10, 529-570 (1996).
4. Carter, J.J. & Galloway, D.A. Humoral immune response to human papillomavirus infection. Clin. Dermatol. 15, 249-259 (1997).
5. Bertoletti, A. & Ferrari, C. Kinetics of the immune response during HBV and HCV infection. Hepatology 38, 4-13 (2003).
6. Doherty, P.C., Christensen, J.P., Belz, G.T., Stevenson, P.G. & Sangster, M.Y. Dissecting the host response to a gamma-herpesvirus. Phil. Trans. R. Soc. Lond. B 356, 581-593 (2001).
7. Callan, M.F. The evolution of antigen-specific CD8 T cell responses after natural primary infection of humans with Epstein-Barr virus. Viral Immunol. 16, 3-16 (2003).
8. Barouch, D.H. et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290, 486-492 (2000).
9. Belyakov, I.M. et al. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nat. Med. 7, 1320-1326 (2001).
10. Rose, N.F. et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106, 539-549 (2001).
11. Shiver, J.W. et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331-335 (2002).
12. Amara, R.R. et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292, 69-74 (2001).
13. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat. Med. 5, 518-525 (1999).
14. Appay, V. et al. Dynamics of T cell responses in HIV infection. J. Immunol. 168, 3660-3666 (2002).
15. Champagne, P. et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 410, 106-111 (2001).
16. Harari, A., Petitpierre, S., Vallelian, F. & Pantaleo, G. Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1 infected subjects with progressive disease: changes after antiretroviral therapy. Blood 103, 966-972 (2003).
17. + T cells. Blood 101, 2711-2720 (2003).
18. + T-cell responses: relationship to viral load in untreated HIV infection. J. Virol. 75, 11983-11991 (2001).
19. Addo, M.M. et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HUV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J. Immunol. 77, 2081-2092 (2003).
20. + T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. 3, 1061-1068 (2002).
21. Rowland-Jones, S.L. et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J. Clin. Invest. 102, 1758-1765 (1998).
22. + lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J. Clin. Invest. 107, 1303-1310 (2001).
23. + responses. J. Clin. Invest. 107, 341-349 (2001).
24. Rosenberg, E.S. et al. Immune control of HIV-1 after early treatment of acute infection. Nature 407, 523-526 (2000).
25. + T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189, 991-998 (1999).
26. + lymphocytes. Science 283, 857-860 (1999).
27. Emini, E.A. et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355, 728-730 (1992).
28. Mascola, J.R. Defining the protective antibody response for HIV-1. Curr. Mol. Med. 3, 209-216 (2003).
29. Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307-312 (2003).
30. Richman, D.D., Wrin, T., Little, S.J. & Petropoulos, C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl Acad. Sci. USA 100, 4144-4149 (2003).
31. Schmitz, J.E. Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus. J. Virol. 77, 2165-2173 (2003).
32. Cohen, J. AIDS vaccine trial produces disappointment and confusion. Science 299, 1290-1291 (2003).
33. Kwong, P.D. et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420, 678-682 (2002).
34. Reitter, J.N., Means, R.E. & Desrosiers, R.C. A role for carbohydrates in immune evasion in AIDS. Nat. Med. 4, 679-684 (1998).
35. Barouch, D.H. et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290, 486-492 (2000).
36. Shiver, J.W. et al. Replication-incompetent retroviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331-335 (2002).
37. Boyer, J.D. et al. Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of β-chemokines. J. Infect. Dis. 181, 476-483 (2000).
38. Cao, H. et al. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study. J. Infect. Dis. 187, 887-895 (2003).
39. Wee, E.G., Patel, S., McMichael, A.J. & Hanke, T. A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques. J. Gen. Virol. 83, 75-80 (2002).
40. Hanke, T. et al. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J. Virol. 73, 7524-7532 (1999).
41. Allen, T.M. et al. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J. Immunol. 164, 4968-4978 (2000).
42. Barouch, D.H. et al. Vaccine-elicited immune responses prevent clinical AIDS in SHIV(89.6P)-infected rhesus monkeys. Immunol. Lett. 79, 57-61 (2001).
43. Kong, W.-P. et al. Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J. Virol. 77, 12764-12772 (2003).
44. Hanke, T. et al. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 16, 439-445 (1998).
45. McConkey, J.S. et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 9, 729-735 (2003).
46. Kent, S.J. et al. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowipox virus. J. Virol. 72, 10180-10188 (1998).
47. Egan, M.A. et al. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1 MN. Env gene. J. Infect. Dis. 171, 1623-1627 (1995).
48. Xin, K.Q. et al. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus. Hum. Gene Ther. 12, 1047-1061 (2001).
49. + T cells. Nature 417, 95-98 (2002).
50. Wu, C.Y. et al. Distinct lineages of T(H)1 cells have differential capacities for memory cell generation in vivo. Nat. Immunol. 3, 852-858 (2002).